Sareum selects SDC-1801 from TYK2 inhibitor program for advancement in autoimmune diseases Sep. 10, 2018
Phase II TORTUGA trial of filgotinib in ankylosing spondylitis meets primary efficacy endpoint Sep. 6, 2018
Phase III study of NeoCart in patients with knee cartilage damage does not meet the primary endpoint Sep. 6, 2018
RSS